EMA Recommends Expanded Approval for Targeted Immunotherapy in Relapsed Mantle Cell Lymphoma

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval for a targeted immunotherapy as a second-line treatment for relapsed mantle cell lymphoma, based on positive Phase III progression-free survival metrics.